FY2017 EPS Estimates for Five Prime Therapeutics, Inc. (FPRX) Lowered by Analyst
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) – Investment analysts at Jefferies Group cut their FY2017 earnings per share estimates for shares of Five Prime Therapeutics in a research note issued on Monday. Jefferies Group analyst E. Yang now anticipates that the biotechnology company will post earnings of ($5.84) per share for the year, down from their prior estimate of ($5.78). Jefferies Group currently has a “Buy” rating and a $52.00 target price on the stock. Jefferies Group also issued estimates for Five Prime Therapeutics’ Q4 2017 earnings at ($1.50) EPS, FY2018 earnings at ($6.65) EPS, FY2019 earnings at ($5.33) EPS, FY2020 earnings at ($4.56) EPS and FY2021 earnings at ($2.23) EPS.
Several other equities analysts have also recently issued reports on the company. Royal Bank Of Canada started coverage on Five Prime Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $41.00 price objective on the stock. BMO Capital Markets increased their target price on Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday. Zacks Investment Research raised Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 target price on the stock in a research report on Monday, October 16th. ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $64.00.
Five Prime Therapeutics (FPRX) opened at $28.83 on Thursday. Five Prime Therapeutics has a one year low of $21.41 and a one year high of $60.98.
Five Prime Therapeutics (NASDAQ:FPRX) last released its earnings results on Monday, November 6th. The biotechnology company reported ($1.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.19). The business had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $16.16 million. Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.72) earnings per share.
In related news, Director William R. Ringo sold 1,800 shares of Five Prime Therapeutics stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $40.26, for a total transaction of $72,468.00. Following the transaction, the director now directly owns 1,200 shares of the company’s stock, valued at $48,312. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director William R. Ringo sold 600 shares of Five Prime Therapeutics stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total value of $27,198.00. Following the transaction, the director now directly owns 600 shares in the company, valued at $27,198. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,400 shares of company stock worth $175,666. 6.50% of the stock is owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. acquired a new position in shares of Five Prime Therapeutics in the 3rd quarter valued at $223,000. Creative Planning boosted its position in Five Prime Therapeutics by 0.8% during the 2nd quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 54 shares during the period. Rockefeller Financial Services Inc. acquired a new stake in Five Prime Therapeutics during the 2nd quarter worth about $210,000. Tudor Investment Corp ET AL boosted its position in Five Prime Therapeutics by 56.8% during the 1st quarter. Tudor Investment Corp ET AL now owns 8,033 shares of the biotechnology company’s stock worth $290,000 after acquiring an additional 2,910 shares during the period. Finally, Dupont Capital Management Corp acquired a new stake in Five Prime Therapeutics during the 3rd quarter worth about $341,000. Institutional investors and hedge funds own 84.08% of the company’s stock.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.